R&D Center
R&D Bases
Six global R&D bases for biologics and chemical drugs operate with efficient synergy, enabling simultaneous overseas development
-
Shenyang
Biologics / Small Molecules
-
Shanghai
Biologics
-
Shenzhen
Biologics
-
Hangzhou
Small Molecules
-
Dongguan
Cell and Gene Therapy / Nucleic Acid Drugs / Biologics
-
Italy
Formulations
R&D Platform
Eight major R&D platforms covering the entire process
CLF² Bispecific Antibody Platform
Common light chain Linear-Fabs-IgG
Advantages of the CLF² R&D Platform
Eliminates heavy- and light-chain mispairing and streamlines downstream manufacturing processes
Exhibits IgG-like physicochemical properties and superior developability
Retains dual functionality and unique synergistic effects of bispecific antibodies
Adopts a flexible and efficient "plug-and-play" design that greatly shortens the R&D cycle
MAP Bispecific Antibody Platform
Multi-directional Association Platform
Advantages of the MAP R&D Platform
Supports customized design and production of mono- and multi-valent bispecific and trispecific antibodies
Adopts stable scFv and linker design to avoid chain mispairing, delivering stability and half-life profiles comparable to those of monoclonal antibodies
Enables direct production of protein-toxin structural molecules in E. coli, featuring high tissue permeability, potent efficacy, and significantly reduced production costs
